Targeting RAS Membrane Association: Back to the Future for Anti-RAS Drug Discovery?
Open accessAbstract
RAS proteins require membrane association for their biologic activity, making this association a logical target for anti-RAS therapeutics. Lipid modification of RAS proteins by a farnesyl isoprenoid is an obligate step in that association, and is an enzymatic process. Accordingly, farnesyltransferase inhibitors (FTI) were developed as potential anti-RAS drugs. The lack of efficacy of FTIs as anticancer drugs was widely seen as indicating that blocking RAS membrane association was a flawed approach to cancer treatment. However, a deeper understanding of RAS modification and trafficking has revealed that this was an erroneous conclusion. In the presence of FTIs, KRAS and NRAS, which are the RAS isoforms most frequently mutated in cancer, become substrates for alternative modification, can still associate with membranes, and can still function. Thus, FTIs failed not because blocking RAS membrane association is an ineffective approach, but because FTIs failed to accomplish that task. Recent findings regarding RAS isoform trafficking and the regulation of RAS subcellular localization have rekindled interest in efforts to target these processes. In particular, improved understanding of the palmitoylation/depalmitoylation cycle that regulates RAS interaction with the plasma membrane, endomembranes, and cytosol, and of the potential importance of RAS chaperones, have led to new approaches. Efforts to validate and target other enzymatically regulated posttranslational modifications are also ongoing. In this review, we revisit lessons learned, describe the current state of the art, and highlight challenging but promising directions to achieve the goal of disrupting RAS membrane association and subcellular localization for anti-RAS drug development. Clin Cancer Res; 21(8); 1819–27. ©2015 AACR. See all articles in this CCR Focus section, “Targeting RAS-Driven Cancers.”
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Inhibiting the activity of farnesyltransferase can prevent the farnesylation of KRAS and reduce its localization to the cell membrane, ultimately inhibiting the activity of KRAS.
“Therefore, inhibiting the activity of farnesyltransferase can prevent the farnesylation of KRAS and reduce its localization to the cell membrane, ultimately inhibiting the activity of KRAS.336”
From Recent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials (2023) · cites this paper as [336]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
A Comprehensive Survey of Ras Mutations in Cancer
Prior, I. A., Lewis, P. D., & Mattos, C. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2612 · Cited by 2,063 · see citing works
Drugging the undruggable RAS: Mission Possible?
Cox, A. D., Fesik, S. W., Kimmelman, A. C., Luo, J., & Der, C. J. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4389 · Cited by 1,997 · see citing works
Self-citationRAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · see citing works
Hancock, J. F., Paterson, H., & Marshall, C. J. (1990) · Cell · doi:10.1016/0092-8674(90)90294-o · Cited by 1,042 · see citing works
K- and N-Ras Are Geranylgeranylated in Cells Treated with Farnesyl Protein Transferase Inhibitors
Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., & Pai, J.-K. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14459 · Cited by 884 · see citing works
An Acylation Cycle Regulates Localization and Activity of Palmitoylated Ras Isoforms
Rocks, O., Peyker, A., Kahms, M., Verveer, P., Koerner, C., Lumbierres, M., Kuhlmann, J., Waldmann, H., Wittinghofer, A., & Bastiaens, P. (2005) · Science · doi:10.1126/science.1105654 · Cited by 866 · see citing works
Stephen, A. G., Esposito, D., Bagni, R. K., & McCormick, F. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.02.017 · Cited by 795 · see citing works
Ras history: The saga continues
Cox, A. D., & Der, C. J. (2010) · Small GTPases · doi:10.4161/sgtp.1.1.12178 · Cited by 706 · see citing works
Self-citationTargeting protein prenylation for cancer therapy
Berndt, N., Hamilton, A. D., & Sebti, S. M. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3151 · Cited by 614 · see citing works
Small molecule inhibition of the KRAS–PDEδ interaction impairs oncogenic KRAS signalling
Zimmermann, G., Papke, B., Ismail, S., Vartak, N., Chandra, A., Hoffmann, M., Hahn, S. A., Triola, G., Wittinghofer, A., Bastiaens, P. I. H., et al. (2013) · Nature · doi:10.1038/nature12205 · Cited by 596 · see citing works
Ras signalling on the endoplasmic reticulum and the Golgi
Chiu, V. K., Bivona, T., Hach, A., Sajous, J. B., Silletti, J., Wiener, H., Johnson, R. L., Cox, A. D., & Philips, M. R. (2002) · Nature Cell Biology · doi:10.1038/ncb783 · Cited by 594 · cited 1× · see citing works
“RAS association with the plasma membrane (PM) and with other membrane compartments upon which signaling occurs (10,11) is promoted by a welldescribed series of post-translational modifications at RAS C-terminal CAAX motifs (Fig.”
BackgroundSelf-citationThe p21 ras C-terminus is required for transformation and membrane association
Willumsen, B. M., Christensen, A., Hubbert, N. L., Papageorge, A. G., & Lowy, D. R. (1984) · Nature · doi:10.1038/310583a0 · Cited by 584 · see citing works
Regulating the regulator: post-translational modification of RAS
Ahearn, I. M., Haigis, K. M., Bar‐Sagi, D., & Philips, M. R. (2011) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3255 · Cited by 560 · see citing works
Self-citationK-ras is an essential gene in the mouse with partial functional overlap with N-rasPreprint
Johnson, L., Greenbaum, D. C., Cichowski, K. M., Mercer, K. L., Murphy, E. A., Schmitt, E. S., Bronson, R. T., Umanoff, H., Edelmann, W., Kucherlapati, R., et al. (1997) · Genes & Development · doi:10.1101/gad.11.19.2468 · Cited by 540 · see citing works
Hancock, J. F., Cadwallader, K. A., Paterson, H., & Marshall, C. J. (1991) · The EMBO Journal · doi:10.1002/j.1460-2075.1991.tb04979.x · Cited by 482 · see citing works
Bivona, T. G., Quatela, S. E., Bodemann, B. O., Ahearn, I. M., Soskis, M. J., Mor, A., Miura, J., Wiener, H. H., Wright, L. P., Saba, S. G., et al. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.012 · Cited by 467 · see citing works
Self-citationThe Palmitoylation Machinery Is a Spatially Organizing System for Peripheral Membrane Proteins
Rocks, O., Gerauer, M., Vartak, N., Koch, S., Huang, Z., Pechlivanis, M., Kuhlmann, J., Brunsveld, L., Chandra, A., Ellinger, B., et al. (2010) · Cell · doi:10.1016/j.cell.2010.04.007 · Cited by 454 · see citing works
Phospholipase Cγ activates Ras on the Golgi apparatus by means of RasGRP1
Bivona, T. G., de Castro, I. P., Ahearn, I. M., Grana, T. M., Chiu, V. K., Lockyer, P. J., Cullen, P. J., Pellicer, À., Cox, A. D., & Philips, M. R. (2003) · Nature · doi:10.1038/nature01806 · Cited by 401 · see citing works
Self-citationSmall-molecule inhibition of APT1 affects Ras localization and signaling.
Dekker, F., Rocks, O., Vartak, N., Menninger, S., Hedberg, C., Balamurugan, R., Wetzel, S., Renner, S., Gerauer, M., Schölermann, B., et al. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.362 · Cited by 401 · see citing works
Direct Demonstration of Geranylgeranylation and Farnesylation of Ki-Ras in Vivo
Rowell, C. A., Kowalczyk, J. J., Lewis, M. D., & Garcia, A. M. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.22.14093 · Cited by 368 · see citing works
Lerner, E. C., Qian, Y., Blaskovich, M. A., Fossum, R. D., Vogt, A., Sun, J., Cox, A. D., Der, C. J., Hamilton, A. D., & Sebti, S. M. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.45.26802 · Cited by 361 · see citing works
Self-citationDHHC9 and GCP16 Constitute a Human Protein Fatty Acyltransferase with Specificity for H- and N-Ras
Swarthout, J. T., Lobo, S., Farh, L., Croke, M., Greentree, W. K., Deschenes, R. J., & Linder, M. E. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m504113200 · Cited by 353 · see citing works
Wright, L. P., & Philips, M. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600004-jlr200 · Cited by 343 · see citing works
Self-citationFarnesol modification of Kirsten-ras exon 4B protein is essential for transformation.
Jackson, J. H., Cochrane, C. G., Bourne, J. R., Solski, P. A., Buss, J. E., & Der, C. J. (1990) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.87.8.3042 · Cited by 338 · see citing works
Self-citationCancer-Associated Protein Kinase C Mutations Reveal Kinase’s Role as Tumor Suppressor
Antal, C. E., Hudson, A., Kang, E., Zanca, C., Wirth, C., Stephenson, N. L., Trotter, E. W., Gallegos, L. L., Miller, C. J., Furnari, F. B., et al. (2015) · Cell · doi:10.1016/j.cell.2015.01.001 · Cited by 331 · see citing works
Chandra, A., Grecco, H. E., Pisupati, V., Perera, D., Cassidy, L., Skoulidis, F., Ismail, S. A., Hedberg, C., Hanzal-Bayer, M., Venkitaraman, A. R., et al. (2012) · Nature Cell Biology · doi:10.1038/ncb2394 · Cited by 325 · see citing works
Depalmitoylated Ras traffics to and from the Golgi complex via a nonvesicular pathway
Goodwin, J., Drake, K. R., Rogers, C., Wright, L. P., Lippincott-Schwartz, J., Philips, M., & Kenworthy, A. (2005) · Journal of Cell Biology · doi:10.1083/jcb.200502063 · Cited by 308 · see citing works
Self-citationMammalian Prenylcysteine Carboxyl Methyltransferase Is in the Endoplasmic Reticulum
Dai, Q., Choy, E., Chiu, V. K., Romano, J. D., Slivka, S. R., Steitz, S. A., Michaelis, S., & Philips, M. R. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.24.15030 · Cited by 296 · see citing works
Self-citationYang, W., Vizio, D. D., Kirchner, M., Steen, H., & Freeman, M. R. (2009) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m800448-mcp200 · Cited by 268 · see citing works
Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo
Ismail, S. A., Chen, Y.-X., Rusinova, A., Chandra, A., Bierbaum, M., Gremer, L., Triola, G., Waldmann, H., Bastiaens, P. I. H., & Wittinghofer, A. (2011) · Nature Chemical Biology · doi:10.1038/nchembio.686 · Cited by 252 · see citing works
Schmick, M., Vartak, N., Papke, B., Kovacevic, M., Truxius, D. C., Rossmannek, L., & Bastiaens, P. I. H. (2014) · Cell · doi:10.1016/j.cell.2014.02.051 · Cited by 243 · see citing works
Lobell, R. B., Omer, C. A., Abrams, M. T., Bhimnathwala, H., Brucker, M. J., Buser, C. A., Davide, J. P., DeSolms, S. J., Dinsmore, C. J., Ellis-Hutchings, M., et al. (2001) · PubMed · Cited by 239 · see citing works
K-Ras4A splice variant is widely expressed in cancer and uses a hybrid membrane-targeting motif
Tsai, F. D., Lopes, M. S., Zhou, M., Court, H., Ponce, O., Fiordalisi, J. J., Gierut, J. J., Cox, A. D., Haigis, K. M., & Philips, M. R. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1412811112 · Cited by 226 · see citing works
Self-citationRas membrane orientation and nanodomain localization generate isoform diversity
Abankwa, D., Gorfe, A. A., Inder, K. L., & Hancock, J. F. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0903907107 · Cited by 223 · see citing works
Metabolic Dependencies in RAS -Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 220 · see citing works
Dislodgment and Accelerated Degradation of Ras
Haklai, R., Gana‐Weisz, M., Elad, G., Paz, A., Marciano, D., Egozi, Y., Ben‐Baruch, G., & Kloog, Y. (1998) · Biochemistry · doi:10.1021/bi972032d · Cited by 195 · see citing works
Schmidt, W. K., Tam, A. S. P., Fujimura‐Kamada, K., & Michaelis, S. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.19.11175 · Cited by 186 · see citing works
Winter-Vann, A. M., Baron, R. A., Wong, W., dela Cruz, J., York, J. D., Gooden, D. M., Bergo, M. O., Young, S. G., Toone, E. J., & Casey, P. J. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408107102 · Cited by 178 · see citing works
Differential inhibitory effects of lovastatin on protein isoprenylation and sterol synthesis.
Sinensky, M. S., Beck, L. A., Leonard, S. S., & Evans, R. (1990) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)45464-0 · Cited by 172 · see citing works
Notch1 Functions as a Tumor Suppressor in a Model of K-ras–Induced Pancreatic Ductal Adenocarcinoma
Hanlon, L., Avila, J. L., Demarest, R. M., Troutman, S. A., Allen, M., Ratti, F., Rustgi, A. K., Stanger, B. Z., Radtke, F., Adsay, V. N., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-4645 · Cited by 172 · see citing works
Isoprenylcysteine Carboxyl Methyltransferase Deficiency in Mice
Bergö, M. O., Leung, G. K. C., Ambroziak, P., Otto, J. C., Casey, P. J., Gomes, A. Q., Seabra, M. C., & Young, S. G. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.c000831200 · Cited by 162 · see citing works
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 162 · see citing works
Zhang, H., Li, S., Doan, T. A., Rieke, F. M., Detwiler, P. B., Frederick, J. M., & Baehr, W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0701681104 · Cited by 160 · see citing works
Rotblat, B., Niv, H., André, S., Kaltner, H., Gabius, H., & Kloog, Y. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-0026 · Cited by 160 · see citing works
Kong, E., Peng, S., Chandra, G., Sarkar, C., Zhang, Z., Bagh, M. B., & Mukherjee, A. B. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.421073 · Cited by 153 · see citing works
Galectin-1 is a novel structural component and a major regulator of h-ras nanoclusters.
Belanis, L., Plowman, S. J., Rotblat, B., Hancock, J., & Kloog, Y. (2008) · Molecular Biology of the Cell · doi:10.1091/mbc.e07-10-1053 · Cited by 147 · see citing works
Absence of the CAAX Endoprotease Rce1: Effects on Cell Growth and Transformation
Bergö, M. O., Ambroziak, P., Gregory, C., George, A. M., Otto, J. C., Kim, E. J.-H., Nagase, H., Casey, P. J., Balmain, A., & Young, S. G. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.1.171-181.2002 · Cited by 142 · see citing works
K-Ras Nanoclustering Is Subverted by Overexpression of the Scaffold Protein Galectin-3
Shalom‐Feuerstein, R., Plowman, S. J., Rotblat, B., Ariotti, N., Tian, T., Hancock, J. F., & Kloog, Y. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-1117 · Cited by 141 · see citing works
Targeting protein lipidation in disease
Resh, M. D. (2012) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2012.01.007 · Cited by 140 · see citing works
Signal Integration by Lipid-Mediated Spatial Cross Talk between Ras Nanoclusters
Zhou, Y., Hong, L., Rodkey, T. L., Ariotti, N., Parton, R. G., & Hancock, J. F. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01227-13 · Cited by 133 · see citing works
Palmitoylation and localisation of RAS isoforms are modulated by the hypervariable linker domain
Laude, A., & Prior, I. A. (2008) · Journal of Cell Science · doi:10.1242/jcs.020107 · Cited by 131 · see citing works
Inhibition of cell growth by lovastatin is independent of ras function.
DeClue, J. E., Vass, W. C., Papageorge, A. G., Lowy, D. R., & Willumsen, B. M. (1991) · PubMed · Cited by 131 · see citing works
Nancy, V., Callebaut, I., Marjou, A. E., & de Gunzburg, J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m109983200 · Cited by 124 · see citing works
Lobell, R. B., Liu, D., Buser, C. A., Davide, J. P., DePuy, E., Hamilton, K., Koblan, K. S., Lee, Y., Mosser, S. D., Motzel, S. L., et al. (2002) · PubMed · Cited by 121 · see citing works
FKBP12 Binds to Acylated H-Ras and Promotes Depalmitoylation
Ahearn, I. M., Tsai, F. D., Court, H., Zhou, M., Jennings, B. C., Ahmed, M., Fehrenbacher, N., Linder, M. E., & Philips, M. R. (2011) · Molecular Cell · doi:10.1016/j.molcel.2011.01.001 · Cited by 115 · see citing works
Self-citationLiu, M., Sjogren, A.-K. M., Karlsson, C., Ibrahim, M. X., Andersson, K., Olofsson, F. J., Wahlstrom, A. M., Dalin, M. G., Yu, H., Chen, Z., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908396107 · Cited by 113 · see citing works
Fendiline Inhibits K-Ras Plasma Membrane Localization and Blocks K-Ras Signal Transmission
van der Hoeven, D., Cho, K.-J., Ma, X., Chigurupati, S., Parton, R. G., & Hancock, J. F. (2012) · Molecular and Cellular Biology · doi:10.1128/mcb.00884-12 · Cited by 112 · see citing works
Marine natural products: Bryostatins in preclinical and clinical studies
Kollár, P., Rajchard, J., Balounová, Z., & Pazourek, J. (2013) · Pharmaceutical Biology · doi:10.3109/13880209.2013.804100 · Cited by 108 · see citing works
Electrostatic Interactions Positively Regulate K-Ras Nanocluster Formation and Function
Plowman, S. J., Ariotti, N., Goodall, A., Parton, R. G., & Hancock, J. F. (2008) · Molecular and Cellular Biology · doi:10.1128/mcb.00050-08 · Cited by 108 · see citing works
Laheru, D. A., Shah, P., Rajeshkumar, N. V., McAllister, F. M., Taylor, G., Goldsweig, H. G., Le, D. T., Donehower, R. C., Jimeno, A., Linden, S., et al. (2012) · Investigational New Drugs · doi:10.1007/s10637-012-9818-6 · Cited by 104 · see citing works
Palmitoylation of oncogenic NRAS is essential for leukemogenesis.
Cuiffo, B., & Ren, R. (2007) · Blood · doi:10.1182/blood-2009-03-213876 · Cited by 101 · see citing works
Vartak, N., Papke, B., Grecco, H., Rossmannek, L., Waldmann, H., Hedberg, C., & Bastiaens, P. (2014) · Biophysical Journal · doi:10.1016/j.bpj.2013.11.024 · Cited by 93 · see citing works
Inactivating Icmt ameliorates K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Liu, M., Lindskog, A., Karlsson, C., Sjogren, A.-K. M., Andersson, K., Young, S. G., & Bergö, M. O. (2008) · Blood · doi:10.1182/blood-2007-06-094060 · Cited by 92 · see citing works
Staurosporines Disrupt Phosphatidylserine Trafficking and Mislocalize Ras Proteins
Cho, K.-J., Park, J.-H., Piggott, A. M., Salim, A. A., Alemayehu, A. G., Parton, R. G., Capon, R. J., Lacey, E., & Hancock, J. F. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.424457 · Cited by 92 · see citing works
Distinct Rates of Palmitate Turnover on Membrane-bound Cellular and Oncogenic H-Ras
Baker, T. L., Zheng, H., Walker, J., Coloff, J. L., & Buss, J. E. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m206956200 · Cited by 89 · see citing works
Oncogenic Synergism between ErbB1, Nucleolin, and Mutant Ras
Farin, K., Trangle, S. S., Haklai, R., Cohen-Or, I., Elad‐Sfadia, G., Reyes-Reyes, M. E., Bates, P. J., Cox, A. D., Kloog, Y., & Pinkas‐Kramarski, R. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2887 · Cited by 86 · see citing works
Self-citationNovel determinants of H-Ras plasma membrane localization and transformation.
Willumsen, B. M., Cox, A. D., Solski, P. A., Der, C. J., & Buss, J. E. (1996) · PubMed · Cited by 86 · see citing works
Self-citationSung, P. J., Tsai, F. D., Vais, H., Court, H., Yang, J., Fehrenbacher, N., Foskett, J. K., & Philips, M. R. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306431110 · Cited by 84 · see citing works
Self-citationXu, J., Hedberg, C., Dekker, F. J., Li, Q., Haigis, K. M., Hwang, E., Waldmann, H., & Shannon, K. (2011) · Blood · doi:10.1182/blood-2011-06-358960 · Cited by 80 · see citing works
Hedberg, C., Dekker, F. J., Rusch, M., Renner, S., Wetzel, S., Vartak, N., Gerding‐Reimers, C., Bon, R. S., Bastiaens, P. I. H., & Waldmann, H. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201102965 · Cited by 80 · see citing works
Targeting of K-Ras 4B by S-trans,trans-farnesyl thiosalicylic acid
Elad, G., Paz, A., Haklai, R., Marciano, D., Cox, A. D., & Kloog, Y. (1999) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/s0167-4889(99)00144-5 · Cited by 77 · see citing works
Self-citationDirect Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75 · see citing works
Spatiotemporal Organization of Ras Signaling: Rasosomes and the Galectin Switch
Ashery, U., Yizhar, O., Rotblat, B., Elad‐Sfadia, G., Barkan, B., Haklai, R., & Kloog, Y. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9059-3 · Cited by 74 · see citing works
Rce1 deficiency accelerates the development of K-RAS–induced myeloproliferative disease
Wahlstrom, A. M., Cutts, B. A., Karlsson, C., Andersson, K., Liu, M., Sjogren, A.-K. M., Swolin, B., Young, S. G., & Bergö, M. O. (2006) · Blood · doi:10.1182/blood-2006-05-024752 · Cited by 72 · see citing works
Nucleophosmin and Nucleolin Regulate K-Ras Plasma Membrane Interactions and MAPK Signal Transduction
Inder, K. L., Lau, C., Loo, D., Chaudhary, N., Goodall, A., Martin, S., Jones, A., van der Hoeven, D., Parton, R. G., Hill, M. M. C., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.001537 · Cited by 71 · see citing works
On the Physiological Importance of Endoproteolysis of CAAX Proteins
Bergö, M. O., Lieu, H. D., Gavino, B. J., Ambroziak, P., Otto, J. C., Casey, P. J., Walker, Q. M., & Young, S. G. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m310081200 · Cited by 67 · see citing works
Small-Molecule Inhibitors of the Rce1p CaaX Protease
Manandhar, S. P., Hildebrandt, E. R., & Schmidt, W. K. (2007) · SLAS DISCOVERY · doi:10.1177/1087057107307226 · Cited by 64 · see citing works
Zimmermann, G., Schultz‐Fademrecht, C., Küchler, P., Murarka, S., Ismail, S., Triola, G., Nußbaumer, P., Wittinghofer, A., & Waldmann, H. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500632s · Cited by 63 · see citing works
Lau, H. Y., Ramanujulu, P. M., Guo, D., Yang, T., Wirawan, M., Casey, P. J., Go, M., & Wang, M. (2014) · Cancer Biology & Therapy · doi:10.4161/cbt.29692 · Cited by 62 · see citing works
Phosphorylation at Ser-181 of Oncogenic KRAS Is Required for Tumor Growth
Barceló, C., Paco, N., Morell, M., Alvarez-Moya, B., Bota‐Rabassedas, N., Jaumot, M., Vilardell, F., Capellá, G., & Agell, N. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1750 · Cited by 62 · see citing works
DeSolms, S. J., Ciccarone, T. M., MacTough, S. C., Shaw, A. W., Buser, C. A., Ellis-Hutchings, M., Fernandes, C., Hamilton, K., Huber, H. E., Kohl, N. E., et al. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm020587n · Cited by 60 · see citing works
Calmodulin Prevents Activation of Ras by PKC in 3T3 Fibroblasts
Villalonga, P., López-Alcalá, C., Chiloeches, A., Gil, J., Marais, R., Bachs, O., & Agell, N. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m202245200 · Cited by 56 · see citing works
Judd, W. R., Slattum, P. M., Hoang, K. C., Bhoite, L. T., Valppu, L., Alberts, G. L., Brown, B., Roth, B. L., Ostanin, K., Huang, L., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200249a · Cited by 56 · see citing works
Court, H., Amoyel, M., Hackman, M., Lee, K. E., Xu, R., Miller, G., Bar‐Sagi, D., Bach, E. A., Bergö, M. O., & Philips, M. R. (2013) · Journal of Clinical Investigation · doi:10.1172/jci65764 · Cited by 54 · see citing works
Self-citationTargeting protein palmitoylation: selective inhibitors and implications in disease
Chavda, B., Arnott, J. A., & Planey, S. L. (2014) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2014.933802 · Cited by 52 · see citing works
Multiple Cellular Proteins Modulate the Dynamics of K-ras Association with the Plasma Membrane
Bhagatji, P., Leventis, R., Rich, R. L., Lin, C., & Silvius, J. R. (2010) · Biophysical Journal · doi:10.1016/j.bpj.2010.10.001 · Cited by 51 · see citing works
Cho, K.-J., Hill, M. M. C., Chigurupati, S., Du, G., Parton, R. G., & Hancock, J. F. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.00989-10 · Cited by 44 · see citing works
Christiansen, J. R., Kolandaivelu, S., Bergö, M. O., & Ramamurthy, V. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1103627108 · Cited by 43 · see citing works
A Distinct Class of Dominant Negative Ras Mutants
Fiordalisi, J. J., Holly, S. P., Johnson, R. L., Parise, L. V., & Cox, A. D. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m107684200 · Cited by 43 · see citing works
Self-citationProfiling and inhibiting reversible palmitoylation
Hernandez, J. L., Majmudar, J. D., & Martin, B. R. (2012) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2012.11.023 · Cited by 42 · see citing works
Boron‐Based Inhibitors of Acyl Protein Thioesterases 1 and 2
Zimmermann, T. J., Bürger, M., Tashiro, E., Kondoh, Y., Martinez, N. E., Görmer, K., Rosin‐Steiner, S., Shimizu, T., Ozaki, S., Mikoshiba, K., et al. (2012) · ChemBioChem · doi:10.1002/cbic.201200571 · Cited by 36 · see citing works
Song, S.-P., Hennig, A., Schubert, K., Markwart, R., Schmidt, P., Prior, I. A., Böhmer, F.-D., & Rubio, I. (2013) · Biochemical Journal · doi:10.1042/bj20121799 · Cited by 27 · see citing works
Lin, X., Jung, J., Kang, D., Xu, B., Zaret, K. S., & Zoghbi, H. Y. (2002) · Gastroenterology · doi:10.1053/gast.2002.34279 · Cited by 22 · see citing works
Chemical approaches for profiling dynamic palmitoylation
Martin, B. R. (2013) · Biochemical Society Transactions · doi:10.1042/bst20120271 · Cited by 18 · see citing works
Dechert, A.-M. R., MacNamara, J. P., Breevoort, S. R., Hildebrandt, E. R., Hembree, N. W., Rea, A. C., McLain, D. E., Porter, S. B., Schmidt, W. K., & Dore, T. M. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.07.041 · Cited by 18 · see citing works
Fueller, F., Bergö, M. O., Young, S. G., Aktories, K., & Schmidt, G. (2006) · Infection and Immunity · doi:10.1128/iai.74.3.1712-1717.2006 · Cited by 18 · see citing works
Tamanoi, F., & Lu, J. (2013) · The Enzymes · doi:10.1016/b978-0-12-420146-0.00008-1 · Cited by 16 · see citing works
Inhibitors of K-Ras Plasma Membrane Localization
Cho, K.-J., van der Hoeven, D., & Hancock, J. F. (2013) · The Enzymes · doi:10.1016/b978-0-12-416749-0.00011-7 · Cited by 16 · see citing works
Chaperone-mediated specificity in Ras and Rap signaling
Azoulay‐Alfaguter, I., Strazza, M., & Mor, A. (2014) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.3109/10409238.2014.989308 · Cited by 12 · see citing works
Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 1 (LYPLA1)
Adibekian, A., Martin, B. R., Chang, J. W., Hsu, K., Tsuboi, K., Bachovchin, D. A., Speers, A. E., Brown, S. J., Spicer, T., Fernández-Vega, V., et al. (2014) · Europe PMC (PubMed Central) · Cited by 11 · see citing works
Characterization of a Selective, Reversible Inhibitor of Lysophospholipase 2 (LYPLA2)
Adibekian, A., Martin, B. R., Chang, J. W., Hsu, K., Tsuboi, K., Bachovchin, D. A., Speers, A. E., Brown, S. J., Spicer, T., Fernández-Vega, V., et al. (2014) · Cited by 10 · see citing works
Kloog, Y., Elad‐Sfadia, G., Haklai, R., & Mor, A. (2013) · The Enzymes · doi:10.1016/b978-0-12-416749-0.00012-9 · Cited by 8 · see citing works
Protein localization: Can too much lipid glue stop Ras?
Cox, A. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.399 · Cited by 6 · see citing works
Self-citation
Flagged first, then by citations
2 of the 105 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Small molecules in targeted cancer therapy: advances, challenges, and future perspectives
Zhong, L., Li, Y., Xiong, L., Wang, W., Wu, M., Yuan, T., Yang, W. M., Tian, C., Miao, Z., Wang, T., et al. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00572-w · Cited by 1,735 · see citing works
KRAS Mutation: From Undruggable to Druggable in Cancer
Huang, L., Guo, Z., Wang, F., & Fu, L. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00780-4 · Cited by 1,127 · see citing works
RAS isoforms and mutations in cancer at a glance
Hobbs, G. A., Der, C. J., & Rossman, K. L. (2016) · Journal of Cell Science · doi:10.1242/jcs.182873 · Cited by 973 · see citing works
Self-citationLu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891 · see citing works
Role of oncogenic KRAS in the diagnosis, prognosis and treatment of pancreatic cancer
Buscail, L., Bournet, B., & Cordelier, P. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0245-4 · Cited by 721 · see citing works
The interplay between cell signalling and the mevalonate pathway in cancer
Mullen, P., Yu, R., Longo, J., Archer, M. C., & Penn, L. Z. (2016) · Nature reviews. Cancer · doi:10.1038/nrc.2016.76 · Cited by 697 · see citing works
Protein prenylation: unique fats make their mark on biology
Wang, M., & Casey, P. J. (2016) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2015.11 · Cited by 550 · see citing works
Genetics and biology of pancreatic ductal adenocarcinoma
Ying, H., Dey, P., Yao, W., Kimmelman, A. C., Draetta, G. F., Maitra, A., & DePinho, R. A. (2016) · Genes & Development · doi:10.1101/gad.275776.115 · Cited by 527 · see citing works
Papke, B., & Der, C. J. (2017) · Science · doi:10.1126/science.aam7622 · Cited by 399 · see citing works
Self-citationRecent advances in targeting the “undruggable” proteins: from drug discovery to clinical trials
Xie, X., Yu, T., Li, X., Zhang, N., Foster, L. J., Peng, C., Huang, W., & He, G. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01589-z · Cited by 396 · see citing works
Targeting the untargetable KRAS in cancer therapy
Liu, P., Wang, Y., & Li, X. (2019) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.03.002 · Cited by 366 · see citing works
Ras Conformational Ensembles, Allostery, and Signaling
Lu, S., Jang, H., Muratcioglu, S., Gursoy, A., Keskin, O., Nussinov, R., & Zhang, J. (2016) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00542 · Cited by 355 · see citing works
McCormick, F. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2662 · Cited by 320 · see citing works
Squamous Cell Cancers: A Unified Perspective on Biology and Genetics
Dotto, G. P., & Rustgi, A. K. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.004 · Cited by 321 · see citing works
KRAS-Mutant non-small cell lung cancer: From biology to therapy
Ferrer, I., Zugazagoitia, J., Herbertz, S., John, W. J., Paz-Ares, L. G., & Schmid‐Bindert, G. (2018) · Lung Cancer · doi:10.1016/j.lungcan.2018.07.013 · Cited by 306 · see citing works
KRAS oncogene in non-small cell lung cancer: clinical perspectives on the treatment of an old target
Román, M., Baraibar, I., López, I., Nadal, E., Rolfo, C., Vicent, S., & Gil-Bazo, I. (2018) · Molecular Cancer · doi:10.1186/s12943-018-0789-x · Cited by 301 · see citing works
Targeting Metalloenzymes for Therapeutic Intervention
Chen, A. Y., Adamek, R. N., Dick, B. L., Credille, C. V., Morrison, C. N., & Cohen, S. M. (2018) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00201 · Cited by 277 · see citing works
Pathological implication of protein post-translational modifications in cancer
Pan, S., & Chen, R. (2022) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2022.101097 · Cited by 272 · see citing works
Metabolic networks in mutant KRAS-driven tumours: tissue specificities and the microenvironment
Kerk, S. A., Papagiannakopoulos, T. Y., Shah, Y. M., & Lyssiotis, C. A. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00375-9 · Cited by 238 · see citing works
Metabolic Dependencies in RAS -Driven Cancers
Kimmelman, A. C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2425 · Cited by 220 · see citing works
Jeong, W.-J., Ro, E. J., & Choi, K.-Y. (2018) · npj Precision Oncology · doi:10.1038/s41698-018-0049-y · Cited by 220 · see citing works
Ras and Rap1: A tale of two GTPases
Shah, S. K., Brock, E. J., Ji, K., & Mattingly, R. R. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.03.005 · Cited by 210 · see citing works
Huang, J., Jiang, G., Song, Q., Gu, X. Q., Meng, H., Wang, X.-L., Song, H., Chen, L., Lin, Y., Jiang, D. M., et al. (2017) · Nature Communications · doi:10.1038/ncomms15144 · Cited by 211 · see citing works
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188 · see citing works
Kinase-mediated RAS signaling via membraneless cytoplasmic protein granules
Tulpule, A., Guan, J., Neel, D. S., Allegakoen, H. R., Lin, Y. P., Brown, D., Chou, Y.-T., Heslin, A., Chatterjee, N., Perati, S., et al. (2021) · Cell · doi:10.1016/j.cell.2021.03.031 · Cited by 189 · see citing works
KRAS Mutant Pancreatic Cancer: No Lone Path to an Effective Treatment
Zeitouni, D., Pylayeva‐Gupta, Y., Der, C. J., & Bryant, K. L. (2016) · Cancers · doi:10.3390/cancers8040045 · Cited by 179 · see citing works
Self-citationThe RASopathies: from pathogenetics to therapeutics
Hebron, K. E., Hernandez, E. R., & Yohe, M. E. (2022) · Disease Models & Mechanisms · doi:10.1242/dmm.049107 · Cited by 167 · see citing works
RAS Synthetic Lethal Screens Revisited: Still Seeking the Elusive Prize?
Downward, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2180 · Cited by 162 · see citing works
Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities
Bournet, B., Buscail, C., Muscari, F., Cordelier, P., & Buscail, L. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.012 · Cited by 164 · see citing works
The improbable targeted therapy: KRAS as an emerging target in non-small cell lung cancer (NSCLC)
Salgia, R., Pharaon, R. R., Mambetsariev, I., Nam, A., & Sattler, M. (2021) · Cell Reports Medicine · doi:10.1016/j.xcrm.2020.100186 · Cited by 163 · see citing works
Progress on Ras/MAPK Signaling Research and Targeting in Blood and Solid Cancers
Dillon, M., Lopez, A. R., Lin, E., Sales, D., Perets, R., & Jain, P. (2021) · Cancers · doi:10.3390/cancers13205059 · Cited by 160 · see citing works
Reiner, D. J. (2016) · WormBook · doi:10.1895/wormbook.1.67.2 · Cited by 152 · see citing works
Hu, H.-F., Ye, Z., Qin, Y., Xu, X.-W., Yu, X.-J., Zhuo, Q.-F., & Ji, S.-R. (2021) · Acta Pharmacologica Sinica · doi:10.1038/s41401-020-00584-2 · Cited by 149 · see citing works
ABHD17 regulation of plasma membrane palmitoylation and N-Ras-dependent cancer growth
Remsberg, J. R., Suciu, R. M., Zambetti, N. A., Hanigan, T. W., Firestone, A. J., Sheth, A. I., Long, A. M., Ngo, N., Lum, K. M., Henry, C. L., et al. (2021) · Nature Chemical Biology · doi:10.1038/s41589-021-00785-8 · Cited by 141 · see citing works
Woensel, M. V., Mathivet, T., Wauthoz, N., Rosière, R., Garg, A. D., Agostinis, P., Mathieu, V., Robert Kiss, A., Lefranc, F., Boon, L., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-01279-1 · Cited by 140 · see citing works
Targeting KRAS Mutant Non-Small-Cell Lung Cancer: Past, Present and Future
Uras, I. Z., Moll, H. P., & Casanova, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21124325 · Cited by 134 · see citing works
Targeting RAS-mutant cancers: is ERK the key?
Ryan, M. B., Der, C., Wang-Gillam, A., & Cox, A. (2015) · Trends in Cancer · doi:10.1016/j.trecan.2015.10.001 · Cited by 125 · see citing works
Self-citationThe role of wild type RAS isoforms in cancer
Zhou, B., Der, C. J., & Cox, A. D. (2016) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2016.07.012 · Cited by 130 · see citing works
Self-citationCurrent therapy of KRAS-mutant lung cancer
Ghimessy, A., Radeczky, P., Laszlo, V., Hegedus, B., Renyi-Vamos, F., Fillinger, J., Klepetko, W., Lang, C., Dome, B., & Megyesfalvi, Z. (2020) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09903-9 · Cited by 115 · see citing works
Oncogenic Ras Isoforms Signaling Specificity at the Membrane
Nussinov, R., Tsai, C., & Jang, H. (2017) · Cancer Research · doi:10.1158/0008-5472.can-17-2727 · Cited by 122 · see citing works
RAL GTPases: Biology and Potential as Therapeutic Targets in Cancer
Yan, C., & Theodorescu, D. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.014415 · Cited by 119 · see citing works
Ntai, I., Fornelli, L., DeHart, C. J., Hutton, J. E., Doubleday, P. F., LeDuc, R. D., van Nispen, A. J., Fellers, R. T., Whiteley, G., Boja, E. S., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1716122115 · Cited by 108 · see citing works
GGTase3 is a newly identified geranylgeranyltransferase targeting a ubiquitin ligase
Kuchay, S., Wang, H., Marzio, A., Jain, K., Homer, H., Fehrenbacher, N., Philips, M. R., Zheng, N., & Pagano, M. (2019) · Nature Structural & Molecular Biology · doi:10.1038/s41594-019-0249-3 · Cited by 108 · see citing works
Self-citationK-Ras protein as a drug target
McCormick, F. (2016) · Journal of Molecular Medicine · doi:10.1007/s00109-016-1382-7 · Cited by 105 · see citing works
Improving Prospects for Targeting RAS
Singh, H., Longo, D. L., & Chabner, B. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.1052 · Cited by 105 · see citing works
Li, Z., Zhao, L., Yu, L., & Wei, M. (2020) · Gastroenterology report · doi:10.1093/gastro/goaa022 · Cited by 104 · see citing works
Small-Molecule Inhibitors Directly Targeting KRAS as Anticancer Therapeutics
Chen, H., Smaill, J. B., Liu, T., Ding, K., & Lu, X. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01312 · Cited by 100 · see citing works
Dietrich, P., Koch, A., FRITZ, V. K., Hartmann, A., Bosserhoff, A., & Hellerbrand, C. (2017) · Gut · doi:10.1136/gutjnl-2017-315402 · Cited by 99 · see citing works
Farnesyl diphosphate synthase is important for the maintenance of glioblastoma stemness
Kim, H. Y., Kim, D.-K., Bae, S.-H., Gwak, H., Jeon, J. H., Kim, J.-K., Lee, B. I., You, H. J., Shin, D. H., Kim, Y.-H., et al. (2018) · Experimental & Molecular Medicine · doi:10.1038/s12276-018-0166-2 · Cited by 99 · see citing works
Biomolecular Condensates and Their Links to Cancer Progression
Cai, D., Liu, Z. J., & Lippincott‐Schwartz, J. (2021) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2021.01.002 · Cited by 98 · see citing works
Aboukameel, A., Muqbil, I., Senapedis, W. T., Baloglu, E., Landesman, Y., Shacham, S., Kauffman, M. G., Philip, P. A., Mohammad, R. M., & Azmi, A. S. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-16-0205 · Cited by 97 · see citing works
Escribá, P. V. (2017) · Biochimica et Biophysica Acta (BBA) - Biomembranes · doi:10.1016/j.bbamem.2017.05.017 · Cited by 96 · see citing works
Miglietta, G., Cogoi, S., Marinello, J., Capranico, G., Tikhomirov, A. S., Shchekotikhin, A. E., & Xodo, L. E. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00622 · Cited by 92 · see citing works
A New View of Ras Isoforms in Cancers
Nussinov, R., Tsai, C., Chakrabarti, M., & Jang, H. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1536 · Cited by 92 · see citing works
Intranasal Perillyl Alcohol for Glioma Therapy: Molecular Mechanisms and Clinical Development
Chen, T. C., da Fonseca, C. O., & Schönthal, A. H. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19123905 · Cited by 88 · see citing works
Drugging “undruggable” genes for cancer treatment: Are we making progress?
Duffy, M. J., & Crown, J. P. (2020) · International Journal of Cancer · doi:10.1002/ijc.33197 · Cited by 85 · see citing works
Targeting small GTPases: emerging grasps on previously untamable targets, pioneered by KRAS
Yin, G., Huang, J., Petela, J., Jiang, H., Zhang, Y., Gong, S., Wu, J., Liu, B., Shi, J., & Gao, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01441-4 · Cited by 87 · see citing works
Photo-induced radical thiol–ene chemistry: a versatile toolbox for peptide-based drug design
Ahangarpour, M., Kavianinia, I., Harris, P. W. R., & Brimble, M. A. (2021) · Chemical Society Reviews · doi:10.1039/d0cs00354a · Cited by 84 · see citing works
Calmodulin and PI3K Signaling in KRAS Cancers
Nussinov, R., Wang, G., Tsai, C., Jang, H., Lu, S., Banerjee, A., Zhang, J., & Gaponenko, V. (2017) · Trends in cancer · doi:10.1016/j.trecan.2017.01.007 · Cited by 78 · see citing works
Tipifarnib Inhibits HRAS-Driven Dedifferentiated Thyroid Cancers
Untch, B. R., Anjos, V. D., García-Rendueles, M. E. R., Knauf, J. A., Krishnamoorthy, G. P., Saqcena, M., Bhanot, U. K., Socci, N. D., Ho, A. L., Ghossein, R. A., et al. (2018) · Cancer Research · doi:10.1158/0008-5472.can-17-1925 · Cited by 78 · see citing works
Direct Modulation of Small GTPase Activity and Function
Cromm, P. M., Spiegel, J., Grossmann, T. N., & Waldmann, H. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201504357 · Cited by 78 · see citing works
Direct Attack on RAS: Intramolecular Communication and Mutation-Specific Effects
Marcus, K., & Mattos, C. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-2148 · Cited by 75 · see citing works
Bahrami, A., Hassanian, S. M., Shahidsales, S., Farjami, Z., Hasanzadeh, M., Anvari, K., Aledavood, A., Maftouh, M., Ferns, G. A., Khazaei, M., et al. (2017) · Journal of Cellular Physiology · doi:10.1002/jcp.25890 · Cited by 74 · see citing works
KRAS-Mutant Non-Small Cell Lung Cancer: An Emerging Promisingly Treatable Subgroup
Xie, M., Xu, X., & Fan, Y. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672612 · Cited by 76 · see citing works
MicroRNA regulation of K-Ras in pancreatic cancer and opportunities for therapeutic intervention
Karmakar, S., Kaushik, G., Nimmakayala, R. K., Rachagani, S., Ponnusamy, M. P., & Batra, S. K. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.11.020 · Cited by 74 · see citing works
Mlakar, V., Morel, E., Mlakar, S. J., Ansari, M., & Gumy‐Pause, F. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01967-x · Cited by 69 · see citing works
New tricks for human farnesyltransferase inhibitor: cancer and beyond
Wang, J., Yao, X., & Huang, J. Y. (2017) · MedChemComm · doi:10.1039/c7md00030h · Cited by 73 · see citing works
Jonckheere, N., Vasseur, R., & SEUNINGEN, I. V. (2017) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2017.01.002 · Cited by 71 · see citing works
Oncogenic KRAS signaling and YAP1/β-catenin: Similar cell cycle control in tumor initiation
Nussinov, R., Tsai, C., Jang, H., Korcsmáros, T., & Csermely, P. (2016) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2016.04.001 · Cited by 70 · see citing works
Integration of Rap1 and Calcium Signaling
Kosuru, R., & Chrzanowska‐Wodnicka, M. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21051616 · Cited by 70 · see citing works
Santarpia, M., Ciappina, G., Spagnolo, C. C., Squeri, A., Passalacqua, M. I., Aguilar, A., Gonzalez-Cao, M., Giovannetti, E., Silvestris, N., & Rosell, R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-639 · Cited by 65 · see citing works
Post-translational modification of RAS proteins
Campbell, S. L., & Philips, M. R. (2021) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2021.06.015 · Cited by 66 · see citing works
Self-citationProgress in targeting RAS with small molecule drugs
McCormick, F. P. (2019) · Biochemical Journal · doi:10.1042/bcj20170441 · Cited by 63 · see citing works
Liu, H., Sun, M., Liu, Z., Kong, C., Kong, W., Ye, J., Gong, J., Huang, D. C. S., & Qian, F. (2019) · Journal of Controlled Release · doi:10.1016/j.jconrel.2019.01.014 · Cited by 64 · see citing works
Rab11b-mediated integrin recycling promotes brain metastatic adaptation and outgrowth
Howe, E. N., Burnette, M. D., Justice, M. E., Schnepp, P. M., Hedrick, V., Clancy, J. W., Guldner, I. H., Lamere, A. T., Li, J., Aryal, U. K., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-16832-2 · Cited by 63 · see citing works
High expression of RAD51 promotes DNA damage repair and survival in KRAS-mutant lung cancer cells
Hu, J., Zhang, Z., Zhao, L., Li, L., Zuo, W., & Han, L. (2019) · BMB Reports · doi:10.5483/bmbrep.2019.52.2.213 · Cited by 62 · see citing works
Targeting KRAS Mutant in Non-Small Cell Lung Cancer: Novel Insights Into Therapeutic Strategies
Désage, A.-L., Léonce, C., Swalduz, A., & Ortiz‐Cuaran, S. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.796832 · Cited by 60 · see citing works
Structure of two G-quadruplexes in equilibrium in the KRAS promoter
Marquevielle, J., Robert, C., Lagrabette, O., Wahid, M., Bourdoncle, A., Xodo, L. E., Mergny, J., & Salgado, G. F. J. (2020) · Nucleic Acids Research · doi:10.1093/nar/gkaa387 · Cited by 61 · see citing works
Protein lipidation in cancer: mechanisms, dysregulation and emerging drug targets
Tate, E. W., Soday, L., de la Lastra, A. L., Wang, M., & Lin, H. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00666-x · Cited by 61 · see citing works
Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
Cheng, F., Liang, H., Butte, A. J., Eng, C., & Nussinov, R. (2018) · Pharmacological Reviews · doi:10.1124/pr.118.016253 · Cited by 58 · see citing works
McCormick, F. P. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-050216-122010 · Cited by 58 · see citing works
Gross, A. M., Frone, M. N., Gripp, K. W., Gelb, B. D., Schoyer, L., Schill, L., Stronach, B. E., Biesecker, L. G., Esposito, D., Hernandez, E. R., et al. (2020) · American Journal of Medical Genetics Part A · doi:10.1002/ajmg.a.61485 · Cited by 57 · see citing works
Boespflug, A. M., Caramel, J., Dalle, S., & Thomas, L. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017708160 · Cited by 57 · see citing works
Intrinsic protein disorder in oncogenic KRAS signaling
Nussinov, R., Jang, H., Tsai, C., Liao, T.-J., Li, S., Fushman, D., & Zhang, J. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2564-3 · Cited by 57 · see citing works
Dietrich, P., Kuphal, S., Spruß, T., Hellerbrand, C., & Bosserhoff, A. (2017) · Oncogene · doi:10.1038/onc.2017.391 · Cited by 54 · see citing works
Asati, V., Mahapatra, D. K., & Bharti, S. K. (2016) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2016.09.049 · Cited by 55 · see citing works
Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma
Liang, C., Qin, Y., Zhang, B., Ji, S., Shi, S., Xu, W., Liu, J., Xiang, J., Liang, D., Hu, Q., et al. (2017) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0296 · Cited by 53 · see citing works
Rce1: mechanism and inhibition
Hampton, S. E., Dore, T. M., & Schmidt, W. K. (2018) · Critical Reviews in Biochemistry and Molecular Biology · doi:10.1080/10409238.2018.1431606 · Cited by 53 · see citing works
Cysteine-based regulation of redox-sensitive Ras small GTPases
Messina, S., Simone, G. D., & Ascenzi, P. (2019) · Redox Biology · doi:10.1016/j.redox.2019.101282 · Cited by 52 · see citing works
Emerging Targets in Non-Small Cell Lung Cancer
Liu, L., Soler, J., Reckamp, K. L., & Sankar, K. N. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms251810046 · Cited by 53 · see citing works
KRAS mutant lung cancer: progress thus far on an elusive therapeutic target
Bhattacharya, S., Socinski, M. A., & Burns, T. F. (2015) · Clinical and Translational Medicine · doi:10.1186/s40169-015-0075-0 · Cited by 50 · see citing works
Barutello, G., Rolih, V., Arigoni, M., Tarone, L., Conti, L., Quaglino, E., Buracco, P., Cavallo, F., & Riccardo, F. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030799 · Cited by 49 · see citing works
MEK inhibitors for the treatment of NRAS mutant melanoma
Sarkisian, S., & Davar, D. (2018) · Drug Design, Development and Therapy · doi:10.2147/dddt.s131721 · Cited by 40 · see citing works
Dietrich, P., Gaza, A., Wormser, L., FRITZ, V. K., Hellerbrand, C., & Bosserhoff, A. (2019) · Neoplasia · doi:10.1016/j.neo.2018.11.011 · Cited by 49 · see citing works
Ponnusamy, A., Sinha, S., Hyde, G. D., Borland, S. J., Taylor, R. F., Pond, E., Eyre, H. J., Inkson, C. A., Gilmore, A. P., Ashton, N., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0196232 · Cited by 48 · see citing works
Marín‐Ramos, N. I., Balabasquer, M., Ortega-Nogales, F. J., Torrecillas, I. R., Gil-Ordóñez, A., Marcos‐Ramiro, B., Aguilar-Garrido, P., Cushman, I., Romero, A., Medrano, F. J., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00145 · Cited by 48 · see citing works
Self-citationMechanisms of Ras Membrane Organization and Signaling: Ras Rocks Again
Abankwa, D., & Gorfe, A. A. (2020) · Biomolecules · doi:10.3390/biom10111522 · Cited by 48 · see citing works
Membrane curvature sensing of the lipid-anchored K-Ras small GTPase
Hong, L., Mu, H., Jean-Francois, F. L., Lakshman, B., Sarkar‐Banerjee, S., Zhuang, Y., Zeng, Y., Gao, W., Zaske, A. M., Nissley, D. V., et al. (2019) · Life Science Alliance · doi:10.26508/lsa.201900343 · Cited by 47 · see citing works
Gadalla, M. R., & Veit, M. (2019) · Expert Opinion on Drug Discovery · doi:10.1080/17460441.2020.1696306 · Cited by 44 · see citing works
Lau, H. Y., Tang, J., Casey, P. J., & Wang, M. (2017) · Oncogene · doi:10.1038/onc.2016.508 · Cited by 46 · see citing works
- Authors
- Cox, A. D., Der, C. J., & Philips, M. R.
- Affiliations
- University of North Carolina at Chapel Hill (US)
- NYU Langone Health (US)
- Venue
- Clinical Cancer Research
- Published
- 2015-04-14
- Volume
- 21
- Issue
- 8
- Pages
- 1819-1827
- ISSN
- 1078-0432 (ISSN-L)
- 1557-3265
- PMC
- PMC4400837
- OpenAlex
- W2129653056
- Cited by
- 351
- References
- 105
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 19 · 2023: 31 · 2022: 30 · 2021: 46 · 2020: 39 · 2019: 29 · 2018: 43 · 2017: 40 · 2016: 28 · 2015: 18 · 2014: 1
- FWCI
- 4.17
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Clinical Cancer Research (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Carolina Digital Repository (University of North Carolina at Chapel Hill) (submittedVersion)
- UNC Libraries
- Funders
- Pancreatic Cancer Action Network
- National Institutes of Health (5r01ca042978-30)
- National Cancer Institute (R01CA116034, R01CA175747, R01CA163489, R01-CA042978, R21CA179193)
- National Institute of General Medical Sciences (R01GM055279)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Sphingolipid Metabolism and Signaling
- Keywords
- farnesyltransferase inhibitors, KRAS, NRAS, depalmitoylation, post-translational modification, RAS-driven cancers
- MeSH terms
- Acetyltransferases, Acylation, Animals, Antineoplastic Agents, Carrier Proteins, Cell Membrane, Humans, Neoplasms, Endopeptidases, Phosphorylation, Protein Kinase C, Thiolester Hydrolases, Signal Transduction, Proto-Oncogene Proteins p21(ras), Protein Prenylation, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Alkyl and Aryl Transferases, Amino Acid Motifs, Protein Transport, Protein Interaction Domains and Motifs, Drug Discovery, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
